Queen's University at Kingston

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1841-10-16

Employees: 1K

Market Cap: -

Website: http://www.queensu.ca

Clinical Trials

Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases

Phase 3

Not yet recruiting

Conditions: Cancer Metastatic

Interventions: Radiation: Standard Conventional Radiotherapy
Radiation: Stereotactic Body Radiotherapy

First Posted Date: 2024-04-30

Last Posted Date: 2024-12-18

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 230

Registration Number: NCT06391242

Using Healthcare Financing and Digital Technology to Improve Hypertension Prevention and Control in Tanzania

Not Applicable

Not yet recruiting

Conditions: Hypertension
Diabetes

Interventions: Other: Nurse-delivered care using WelTel check-ins and BCC SMS
Other: Community-based peer-support model

First Posted Date: 2024-04-23

Last Posted Date: 2024-05-06

Lead Sponsor: Queen's University

Target Recruit Count: 1320

Registration Number: NCT06379750

Determining the Impact of a Physiotherapist-led Primary Care Model for Hip and Knee Pain - A Cluster Trial

Not Applicable

Active, not recruiting

Conditions: Knee Osteoarthritis
Hip Osteoarthritis

Interventions: Other: Physiotherapist-led primary care model for hip and knee pain
Other: Usual physician-led primary care model for hip and knee pain

First Posted Date: 2024-04-10

Last Posted Date: 2024-12-05

Lead Sponsor: Queen's University

Target Recruit Count: 728

Registration Number: NCT06358521

Locations: 🇨🇦
Queen's University, Kingston, Ontario, Canada

STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision

Not Applicable

Recruiting

Conditions: Vulvar Squamous Cell Carcinoma

Interventions: Other: Active Surveillance
Procedure: Surgery

First Posted Date: 2024-04-10

Last Posted Date: 2024-12-16

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 249

Registration Number: NCT06358469

Locations: 🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada

Evaluating Changes in Skeletal Muscle Proteins Following Resistance Exercise and Single-Leg Disuse

Not Applicable

Recruiting

Conditions: Skeletal Muscle Hypertrophy
Healthy
Skeletal Muscle Atrophy

Interventions: Other: Immobilization
Other: Resistance training

First Posted Date: 2024-04-05

Last Posted Date: 2024-10-17

Lead Sponsor: Queen's University

Target Recruit Count: 14

Registration Number: NCT06350591

Locations: 🇨🇦
School of Kinesiology and Health Studies, Kingston, Ontario, Canada

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Phase 3

Recruiting

Conditions: Prostate Cancer

Interventions: Radiation: Radiation
Radiation: Radiation SBRT only
Drug: ADT

First Posted Date: 2024-02-01

Last Posted Date: 2024-12-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 710

Registration Number: NCT06235697

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study

Phase 4

Not yet recruiting

Conditions: Generalized Anxiety Disorder

Interventions: Drug: L-methylfolate

First Posted Date: 2024-01-23

Last Posted Date: 2024-01-24

Lead Sponsor: Queen's University

Target Recruit Count: 10

Registration Number: NCT06218030

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Phase 3

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: Fluoruracil
Drug: Leucovorin
Drug: Capecitabine
Drug: Oxaliplatin
Radiation: Radiation

First Posted Date: 2024-01-16

Last Posted Date: 2024-12-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 250

Registration Number: NCT06205485

Locations: 🇺🇸
Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States
🇺🇸
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 50 locations

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Daratumumab
Drug: Dexamethasone

First Posted Date: 2023-12-27

Last Posted Date: 2024-12-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 559

Registration Number: NCT06182774

Locations: 🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada
🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada

and more 15 locations

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Phase 2

Recruiting

Conditions: Gastroesophageal Adenocarcinoma

Interventions: Drug: Paclitaxel
Drug: Ramucirumab
Drug: Zanidatamab

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 168

Registration Number: NCT06043427

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 12 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy